$LH

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.

Piper Sandler raised Labcorp's price target to $309 from $300 but kept a 'Neutral' rating. The average target is $342.94, suggesting 1.6% upside, while the highest target is $385, implying 14%.

Labcorp has launched a hepatitis D reflex test, automatically screening for hepatitis D in patients who test positive for hepatitis B. The test aims to improve early diagnosis and streamline workflows. According to Labcorp, fewer than 20% of hepatitis B patients are currently screened for hepatitis D, despite an estimated 70,000 to 150,000 active cases in the US. The company hopes this will lead to earlier treatment and better patient outcomes.

Labcorp (NYSE: LH) announced it will offer the Elecsys® pTau-217 blood test, the first FDA-cleared single-biomarker test to detect Alzheimer's disease pathology. Developed by Roche Diagnostics, the test measures phosphorylated Tau 217, an indicator of amyloid pathology, in individuals 55 and older with cognitive decline symptoms. The test will be available nationwide in primary and specialty care settings, providing a standardized approach to patient assessment. Labcorp plans to make the test av

HSBC increased its price target for Labcorp Holdings to $330 from $270. The company's shares are currently trading at $336.34, up 1.06% for the day and 5.72% year-to-date. This adjustment is based on various composite ratings and analyst recommendations.

Analysts updated recommendations for multiple companies. Kimberly-Clark (KMB) was downgraded to underperform with a higher price target. Palantir (PLTR) was upgraded to buy. Snap (SNAP) was upgraded to buy with a slightly lower target. Accenture (ACN) and others saw price target increases.

ANDERSON KERRII B sold 3,000 shares of LABCORP HOLDINGS INC. (LH) at $318.02 ($0.95M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Labcorp (NYSE: LH) and the National Association of Community Health Centers (NACHC) announced a strategic alliance to support leadership development, practice improvement and community health initiatives across the Community Health Center network. The groups will launch the NACHC Leadership Exchange for Chief Medical Officers and collaborate on education, evidence generation, and use of de-identified lab data.

Labcorp Holdings (NYSE:LH) said Megan D. Bailey will resign as EVP and President, Central Laboratories and International on Sept. 4, 2026, with Brian J. Caveney expanding leadership. Labcorp also began nationwide offering Roche’s VENTANA PTEN (SP218) RxDx assay for prostate cancer companion diagnostics. The piece cites a 2029 revenue target of $16.6B and earnings of $1.4B.

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.